Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Molecular Neurodegeneration
Published in: Molecular Neurodegeneration 1/2017

Open Access 01-12-2017 | Review

The Trojan horse - neuroinflammatory impact of T cells in neurodegenerative diseases

Authors: Annika Sommer, Beate Winner, Iryna Prots

Published in: Molecular Neurodegeneration | Issue 1/2017

Login to get access

Abstract

Neuronal degeneration is a common mechanism of many neurological diseases including Parkinson’s disease (PD), Alzheimer’s disease (AD), and Multiple Sclerosis (MS). While AD and PD are classical neurodegenerative diseases, the primary pathology in MS is driven by autoimmune inflammation, attacking oligodendrocytes and thereby inducing neurodegeneration. In AD and PD, immune cells are also considered to play an important role in the disease progression. While the role of local central nervous system (CNS) innate immune cells is well described, a potential influence of adaptive immune cells in PD and AD is not yet fully understood.
Here, we aim to summarize findings concerning adaptive immune cells in PD pathogenesis and compare them to AD and MS. In the first part, we focus on disease-specific alterations of lymphocytes in the circulating blood. Subsequently, we describe what is known about CNS-infiltrated lymphocytes and mechanisms of their infiltration. Finally, we summarize published data and try to understand the mechanisms of how lymphocytes contribute to neurodegeneration in PD, AD, and MS.
Lymphocytes are critically involved in the pathogenesis of MS, and clarifying the role of lymphocytes in PD and AD pathogenesis might lead to an identification of a common signature of lymphocytes in neurodegeneration and thus pave the road towards novel treatment options.
Literature
1.
Fahn S. Description of Parkinson’s disease as a clinical syndrome. Ann N Y Acad Sci. 2003;991:1–14.CrossRefPubMed
2.
3.
Braak H, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003;24(2):197–211.CrossRefPubMed
4.
5.
Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. Nat Rev Immunol. 2015;15(9):545–58.CrossRefPubMed
6.
Heneka MT, Kummer MP, Latz E. Innate immune activation in neurodegenerative disease. Nat Rev Immunol. 2014;14(7):463–77.CrossRefPubMed
7.
8.
9.
Romeu MA, et al. Lymphocyte immunophenotyping by flow cytometry in normal adults. Comparison of fresh whole blood lysis technique, Ficoll-Paque separation and cryopreservation. J Immunol Methods. 1992;154(1):7–10.CrossRefPubMed
10.
Moradi B, et al. CD4(+)CD25(+)/highCD127low/(−) regulatory T cells are enriched in rheumatoid arthritis and osteoarthritis joints--analysis of frequency and phenotype in synovial membrane, synovial fluid and peripheral blood. Arthritis Res Ther. 2014;16(2):R97.CrossRefPubMedPubMedCentral
11.
12.
Saunders JA, et al. CD4+ regulatory and effector/memory T cell subsets profile motor dysfunction in Parkinson's disease. J NeuroImmune Pharmacol. 2012;7(4):927–38.CrossRefPubMedPubMedCentral
13.
Bas J, et al. Lymphocyte populations in Parkinson's disease and in rat models of parkinsonism. J Neuroimmunol. 2001;113(1):146–52.CrossRefPubMed
14.
Baba Y, et al. Alterations of T-lymphocyte populations in Parkinson disease. Parkinsonism Relat Disord. 2005;11(8):493–8.CrossRefPubMed
15.
Stevens CH, et al. Reduced T helper and B lymphocytes in Parkinson's disease. J Neuroimmunol. 2012;252(1–2):95–9.CrossRefPubMed
16.
17.
Niwa F, et al. Effects of peripheral lymphocyte subpopulations and the clinical correlation with Parkinson's disease. Geriatr Gerontol Int. 2012;12(1):102–7.CrossRefPubMed
18.
Chen S, et al. Increased abundance of myeloid-derived suppressor cells and Th17 cells in peripheral blood of newly-diagnosed Parkinson's disease patients. Neurosci Lett. 2017;648:21–5.CrossRefPubMed
19.
Nie K, et al. Polymorphisms in immune/inflammatory cytokine genes are related to Parkinson's disease with cognitive impairment in the Han Chinese population. Neurosci Lett. 2013;541:111–5.CrossRefPubMed
20.
Harrington LE, Mangan PR, Weaver CT. Expanding the effector CD4 T-cell repertoire: the Th17 lineage. Curr Opin Immunol. 2006;18(3):349–56.CrossRefPubMed
21.
Sakaguchi S, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995;155(3):1151–64.PubMed
22.
Baecher-Allan, C., et al., CD4+CD25+ regulatory cells from human peripheral blood express very high levels of CD25 ex vivo. Novartis Found Symp, 2003 252: p 67–88; discussion 88-91, 106–14.
23.
Thornton AM, Shevach EM. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med. 1998;188(2):287–96.CrossRefPubMedPubMedCentral
24.
Piccirillo CA, Shevach EM. Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J Immunol. 2001;167(3):1137–40.CrossRefPubMed
25.
Rosenkranz D, et al. Higher frequency of regulatory T cells in the elderly and increased suppressive activity in neurodegeneration. J Neuroimmunol. 2007;188(1–2):117–27.CrossRefPubMed
26.
27.
28.
D.A. Cook, G.T.K., a.F. Cintron, Laura M. Butkovich, Kyle B. Fraserm J. Chang, N. Grigoryan, S.A. Factor, Andrew B. West, J.M. Boss, M.G. Tansey, LRRK2 levels in immune cells are increased in Parkinson’s disease. Nature 2017.
29.
Fiszer U, et al. Parkinson's disease and immunological abnormalities: increase of HLA-DR expression on monocytes in cerebrospinal fluid and of CD45RO+ T cells in peripheral blood. Acta Neurol Scand. 1994;90(3):160–6.CrossRefPubMed
30.
Besser MJ, Ganor Y, Levite M. Dopamine by itself activates either D2, D3 or D1/D5 dopaminergic receptors in normal human T-cells and triggers the selective secretion of either IL-10. TNFalpha or both J Neuroimmunol. 2005;169(1–2):161–71.CrossRefPubMed
31.
Carr L, Tucker A, Fernandez-Botran R. In vivo administration of L-dopa or dopamine decreases the number of splenic IFN gamma-producing cells. J Neuroimmunol. 2003;137(1–2):87–93.CrossRefPubMed
32.
Double KL, et al. Anti-melanin antibodies are increased in sera in Parkinson's disease. Exp Neurol. 2009;217(2):297–301.CrossRefPubMed
33.
Yanamandra K, et al. Alpha-synuclein reactive antibodies as diagnostic biomarkers in blood sera of Parkinson's disease patients. PLoS One. 2011;6(4):e18513.CrossRefPubMedPubMedCentral
34.
Zappia M, et al. Anti-GM1 ganglioside antibodies in Parkinson's disease. Acta Neurol Scand. 2002;106(1):54–7.CrossRefPubMed
35.
De Virgilio A, et al. Parkinson's disease: autoimmunity and neuroinflammation. Autoimmun Rev. 2016;15(10):1005–11.CrossRefPubMed
36.
Sulzer D, et al. T cells from patients with Parkinson's disease recognize alpha-synuclein peptides. Nature. 2017;546(7660):656–61.CrossRefPubMed
37.
Mosley RL, Gendelman HE. T cells and Parkinson's disease. Lancet Neurol. 2017;
38.
Richartz-Salzburger E, et al. Altered lymphocyte distribution in Alzheimer's disease. J Psychiatr Res. 2007;41(1–2):174–8.CrossRefPubMed
39.
40.
Pellicano M, et al. Immune profiling of Alzheimer patients. J Neuroimmunol. 2012;242(1–2):52–9.CrossRefPubMed
41.
Saresella M, et al. Increased activity of Th-17 and Th-9 lymphocytes and a skewing of the post-thymic differentiation pathway are seen in Alzheimer's disease. Brain Behav Immun. 2011;25(3):539–47.CrossRefPubMed
42.
Elyaman W, et al. IL-9 induces differentiation of TH17 cells and enhances function of FoxP3+ natural regulatory T cells. Proc Natl Acad Sci U S A. 2009;106(31):12885–90.CrossRefPubMedPubMedCentral
43.
Nath A, et al. Autoantibodies to amyloid beta-peptide (Abeta) are increased in Alzheimer's disease patients and Abeta antibodies can enhance Abeta neurotoxicity: implications for disease pathogenesis and vaccine development. NeuroMolecular Med. 2003;3(1):29–39.CrossRefPubMed
44.
Gruden MA, et al. Autoimmune responses to amyloid structures of Abeta (25-35) peptide and human lysozyme in the serum of patients with progressive Alzheimer's disease. Dement Geriatr Cogn Disord. 2004;18(2):165–71.CrossRefPubMed
45.
Mruthinti S, et al. Autoimmunity in Alzheimer's disease: increased levels of circulating IgGs binding Abeta and RAGE peptides. Neurobiol Aging. 2004;25(8):1023–32.CrossRefPubMed
46.
Thompson AJ, et al. Peripheral blood T lymphocyte changes in multiple sclerosis: a marker of disease progression rather than of relapse? J Neurol Neurosurg Psychiatry. 1986;49(8):905–12.CrossRefPubMedPubMedCentral
47.
Durelli L, et al. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta. Ann Neurol. 2009;65(5):499–509.CrossRefPubMed
48.
Venken K, et al. Compromised CD4+ CD25(high) regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level. Immunology. 2008;123(1):79–89.CrossRefPubMedPubMedCentral
49.
Mogi M, et al. Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci Lett. 1994;180(2):147–50.CrossRefPubMed
50.
Nagatsu T, et al. Changes in cytokines and neurotrophins in Parkinson's disease. J Neural Transm Suppl. 2000;60:277–90.
51.
Yu SY, et al. Potential biomarkers relating pathological proteins, neuroinflammatory factors and free radicals in PD patients with cognitive impairment: a cross-sectional study. BMC Neurol. 2014;14:113.CrossRefPubMedPubMedCentral
52.
53.
Stieler J, et al. Multivariate analysis of differential lymphocyte cell cycle activity in Alzheimer's disease. Neurobiol Aging. 2012;33(2):234–41.CrossRefPubMed
54.
Alberio T, et al. Parkinson's disease plasma biomarkers: an automated literature analysis followed by experimental validation. J Proteome. 2013;90:107–14.CrossRef
55.
McGeer PL, et al. Rate of cell death in parkinsonism indicates active neuropathological process. Ann Neurol. 1988;24(4):574–6.CrossRefPubMed
56.
Brochard V, et al. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest. 2009;119(1):182–92.PubMed
57.
58.
59.
Togo T, et al. Occurrence of T cells in the brain of Alzheimer's disease and other neurological diseases. J Neuroimmunol. 2002;124(1–2):83–92.CrossRefPubMed
60.
61.
Babbe H, et al. Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med. 2000;192(3):393–404.CrossRefPubMedPubMedCentral
62.
Schwartz M, Baruch K. The resolution of neuroinflammation in neurodegeneration: leukocyte recruitment via the choroid plexus. EMBO J. 2014;33(1):7–22.CrossRefPubMed
63.
Shechter R, Schwartz M. Harnessing monocyte-derived macrophages to control central nervous system pathologies: no longer 'if' but 'how'. J Pathol. 2013;229(2):332–46.CrossRefPubMed
64.
Engelhardt B, Wolburg-Buchholz K, Wolburg H. Involvement of the choroid plexus in central nervous system inflammation. Microsc Res Tech. 2001;52(1):112–29.CrossRefPubMed
65.
Mietelska-Porowska A, Wojda U. T lymphocytes and inflammatory mediators in the interplay between brain and blood in Alzheimer's disease: potential pools of new biomarkers. J Immunol Res. 2017;2017:4626540.CrossRefPubMedPubMedCentral
66.
Larochelle C, Alvarez JI, Prat A. How do immune cells overcome the blood-brain barrier in multiple sclerosis? FEBS Lett. 2011;585(23):3770–80.CrossRefPubMed
67.
Yarlagadda A, Alfson E, Clayton AH. The blood brain barrier and the role of cytokines in neuropsychiatry. Psychiatry (Edgmont). 2009;6(11):18–22.
68.
Liu Z, et al. Th17 cells induce dopaminergic neuronal death via LFA-1/ICAM-1 interaction in a mouse model of Parkinson's disease. Mol Neurobiol. 2016;
69.
Reynolds AD, et al. Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson's disease. J Leukoc Biol. 2007;82(5):1083–94.CrossRefPubMed
70.
Reynolds AD, et al. Nitrated {alpha}-synuclein-induced alterations in microglial immunity are regulated by CD4+ T cell subsets. J Immunol. 2009;182(7):4137–49.CrossRefPubMedPubMedCentral
71.
Rowin J, et al. Granulocyte macrophage colony-stimulating factor treatment of a patient in myasthenic crisis: effects on regulatory T cells. Muscle Nerve. 2012;46(3):449–53.CrossRefPubMedPubMedCentral
72.
Gendelman HE, et al. Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson's disease trial. NPJ Parkinsons Dis. 2017;3:10.CrossRefPubMedPubMedCentral
73.
Pierce S, Coetzee GA. Parkinson's disease-associated genetic variation is linked to quantitative expression of inflammatory genes. PLoS One. 2017;12(4):e0175882.CrossRefPubMedPubMedCentral
74.
Nalls MA, et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat Genet. 2014;46(9):989–93.CrossRefPubMedPubMedCentral
75.
Gagliano SA, et al. Genomics implicates adaptive and innate immunity in Alzheimer's and Parkinson's diseases. Ann Clin Transl Neurol. 2016;3(12):924–33.CrossRefPubMedPubMedCentral
76.
Browne TC, et al. IFN-gamma production by amyloid beta-specific Th1 cells promotes microglial activation and increases plaque burden in a mouse model of Alzheimer's disease. J Immunol. 2013;190(5):2241–51.CrossRefPubMed
77.
78.
Siffrin V, et al. In vivo imaging of partially reversible th17 cell-induced neuronal dysfunction in the course of encephalomyelitis. Immunity. 2010;33(3):424–36.CrossRefPubMed
79.
Tanabe S, Yamashita T. Repulsive guidance molecule-a is involved in Th17-cell-induced neurodegeneration in autoimmune encephalomyelitis. Cell Rep. 2014;9(4):1459–70.CrossRefPubMed
80.
Farh KK, et al. Genetic and epigenetic fine mapping of causal autoimmune disease variants. Nature. 2015;518(7539):337–43.CrossRefPubMed
81.
Sanchez-Guajardo V, et al. Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson's disease. PLoS One. 2010;5(1):e8784.CrossRefPubMedPubMedCentral
82.
83.
Ryan SD, et al. Isogenic human iPSC Parkinson's model shows nitrosative stress-induced dysfunction in MEF2-PGC1alpha transcription. Cell. 2013;155(6):1351–64.CrossRefPubMedPubMedCentral
Metadata
Title
The Trojan horse - neuroinflammatory impact of T cells in neurodegenerative diseases
Authors
Annika Sommer
Beate Winner
Iryna Prots
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Molecular Neurodegeneration / Issue 1/2017
Electronic ISSN: 1750-1326
DOI
https://doi.org/10.1186/s13024-017-0222-8

Other articles of this Issue 1/2017

Molecular Neurodegeneration 1/2017 Go to the issue

Research article

A validated antibody panel for the characterization of tau post-translational modifications

Research article

Prevention of C5aR1 signaling delays microglial inflammatory polarization, favors clearance pathways and suppresses cognitive loss

Review

Iron regulatory protein (IRP)-iron responsive element (IRE) signaling pathway in human neurodegenerative diseases

Research article

Spatiotemporal progression of ubiquitin-proteasome system inhibition after status epilepticus suggests protective adaptation against hippocampal injury

Research article

Presenilins regulate synaptic plasticity and mitochondrial calcium homeostasis in the hippocampal mossy fiber pathway

Research article

Autoimmune antibody decline in Parkinson’s disease and Multiple System Atrophy; a step towards immunotherapeutic strategies